By Sarina Isaacs
Shares of ARS Pharmaceuticals were sharply higher after the biopharmaceutical company posted earnings and revenue that came in well above Wall Street views.
The stock was up 22% at $14.22 in early trading. That puts it at a gain of more than 60% over the past 12 months.
The San Diego-based biopharmaceutical company, whose main product is an emergency nasal spray for severe allergic reactions, on Thursday reported a profit of $49.9 million, or 48 cents a share.
Analysts were anticipating a loss of 24 cents per share, and a year earlier the company said it lost $7.2 million.
Revenue for the quarter came to $86.6 million, surpassing analyst expectations for $5.7 million.
ARS said its neffy nasal-spray product brought in $7.3 million in net revenue from its late-September launch through the end of the year.
The company added that, with $314 million in cash, cash equivalents and short-term investments as of Dec. 31, it continues to expect its financial position to support its operating plans for at least the next three years.
Write to Sarina Isaacs at sarina.isaacw@wsj.com
(END) Dow Jones Newswires
March 20, 2025 10:03 ET (14:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。